WXIBF Wuxi Biologics Cayman Inc. Forecast, Technical & Fundamental Analysis

WXIBF's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for WXIBF turned positive on December 30, 2024. Looking at past instances where WXIBF's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on January 02, 2025. You may want to consider a long position or call options on WXIBF as a result. In of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

WXIBF moved above its 50-day moving average on December 30, 2024 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for WXIBF crossed bullishly above the 50-day moving average on January 06, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 67 cases where WXIBF's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. WXIBF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.700) is normal, around the industry mean (14.744). P/E Ratio (28.110) is within average values for comparable stocks, (88.252). Projected Growth (PEG Ratio) (1.477) is also within normal values, averaging (1.853). WXIBF has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (4.239) is also within normal values, averaging (264.079).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. WXIBF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.